 Connection
Larry Moreland to Lymphocyte Activation
This is a "connection" page, showing publications Larry Moreland has written about Lymphocyte Activation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.569 |
|
|
|
-
Inamo J, Keegan J, Griffith A, Ghosh T, Horisberger A, Howard K, Pulford JF, Murzin E, Hancock B, Dominguez ST, Gurra MG, Gurajala S, Jonsson AH, Seifert JA, Feser ML, Norris JM, Cao Y, Apruzzese W, Bridges SL, Bykerk VP, Goodman S, Donlin LT, Firestein GS, Bathon JM, Hughes LB, Filer A, Pitzalis C, Anolik JH, Moreland L, Hacohen N, Guthridge JM, James JA, Cuda CM, Perlman H, Brenner MB, Raychaudhuri S, Sparks JA, Holers VM, Deane KD, Lederer J, Rao DA, Zhang F. Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. J Clin Invest. 2025 Mar 17; 135(6).
Score: 0.167
-
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003 Nov 13; 349(20):1907-15.
Score: 0.152
-
Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006 03; 5(3):185-6.
Score: 0.045
-
Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2005 Sep; 5(9):1245-54.
Score: 0.043
-
Dunlap G, Wagner A, Meednu N, Wang R, Zhang F, Ekabe JC, Jonsson AH, Wei K, Sakaue S, Nathan A, Bykerk VP, Donlin LT, Goodman SM, Firestein GS, Boyle DL, Holers VM, Moreland LW, Tabechian D, Pitzalis C, Filer A, Raychaudhuri S, Brenner MB, Thakar J, McDavid A, Rao DA, Anolik JH. Clonal associations between lymphocyte subsets and functional states in rheumatoid arthritis synovium. Nat Commun. 2024 Jun 11; 15(1):4991.
Score: 0.040
-
Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002 Apr; 103(1):13-21.
Score: 0.034
-
Moreland LW, Heck LW, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O'Connor RD, Morgan EE, Diveley JP, Richieri SP, Carlo DJ, Brostoff SW. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol. 1996 Aug; 23(8):1353-62.
Score: 0.023
-
Moreland LW, Heck LW, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O'Connor RD, Morgan EE, Diveley JP, Chieffo NM, et al. V beta 17 T-cell receptor peptide vaccine. Results of a phase I dose-finding study in patients with rheumatoid arthritis. Ann N Y Acad Sci. 1995 Jul 07; 756:211-4.
Score: 0.021
-
Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgarriff C, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 1993 Mar; 36(3):307-18.
Score: 0.018
-
Moreland LW, Heck LW, Sullivan W, Pratt PW, Koopman WJ. New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. Am J Med Sci. 1993 Jan; 305(1):40-51.
Score: 0.018
-
St Clair EW, Cohen SB, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ. Treatment of rheumatoid arthritis with a DR4/1 peptide. J Rheumatol. 2000 Aug; 27(8):1855-63.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|